Qiming Corporate GP VI, Ltd. sold $8.6M of ALMR (indirect holdings)

Qiming Corporate GP VI, Ltd. sold 280,458 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $30.56 ($29.35–$31.07, $8.57M total) across 20 trades over 2026-10-23 to 2026-10-26. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).

Original reporting
SEC EDGAR · Qiming Corporate GP VI, Ltd., Qiming Managing Directors Fund VI, L.P., Qiming Venture Partners VI, L.P., Qiming GP VIII, LLC, Qiming Venture Partners VIII Investments, LLC, Qiming GP VIII-HC, LLC, Qiming Venture Partners VIII-HC, L.P.
Published Oct 27, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMR
Bearish
medium confidence
Mentioned
$ALMR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMRBearishLow
01

Why it matters

The disclosed sale reduces insider ownership to ~1.74M shares, potentially influencing investor perception.

02

Market read

Primary insider sale for a micro‑cap biotech; modest trading relevance.

03

What to watch

The 10b5‑1 plan was not pre‑arranged, indicating the sale was discretionary.

Relevance 6/10Novelty 4/10Timing: post‑market today

Background

Form 4 filings disclose insider transactions; Qiming entities collectively own ~10% of ALMR.

Company-level read

Ticker impact

$ALMRBearishMedium confidence
Context

Form 4 shows Qiming Corporate GP VI, Ltd. sold ~280k shares of ALMR for $8.57M, reducing its stake.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

The sale is sizable for a micro‑cap and was executed at market prices, suggesting a neutral to negative sentiment.

Market effects

Minimal impact on the broader biotech sector; only reflects a single insider's position.

No regional effect beyond the company's share price.

Limited to investors tracking micro‑cap biotech stocks.

Counterpoint

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Alamar Biosciences, Inc.

    Biotech firm listed on NASDAQ under ticker ALMR.

  • Qiming Corporate GP VI, Ltd.

    10% owner of ALMR filing the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMRMed

Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript

Alamar Biosciences (ALMR) reported Q3 2026 revenue growth of 68% YoY, with consumables up 79%. Gross margin improved to 61.5%. The company raised full-year guidance and announced partnerships with U.K. Biobank and GSK, totaling over 140,000 samples. ALMR added 35 publications, bringing the total to over 200, and strengthened its leadership team.

$ALMRMed

Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript

Alamar Biosciences (ALMR) reported Q3 2026 revenue of $33.5M, up 68% YoY, with gross margin at 61.5%. Net loss was $13.3M. Full-year revenue guidance raised to $121M-$123M. Company finalized large-scale studies with UK Biobank and GSK, focusing on neurodegenerative and inflammatory diseases. Cash position at $231.5M supports expansion plans. President Todd White to retire by year-end.

$ALMRMed

Alamar Biosciences Inc (ALMR) (Q3 2026) Earnings Call Highlights: Revenue Jumps 68%

Alamar Biosciences Inc (ALMR) reported Q3 2026 revenue of $33.5M, up 68% YoY, with consumables revenue representing 53% of total revenue. Gross margin reached 61.5%. Full-year guidance was raised to $121-123M. Net loss widened to $13.3M. The company secured partnerships with UK Biobank and GSK. Q4 revenue guidance implies flat sequential growth, raising concerns about near-term momentum.

$ALMRMed

Alamar Biosciences Q3 Earnings Call Highlights

Alamar Biosciences (ALMR) reported Q3 earnings, with revenue up 64% YoY. Key projects include UK Biobank work and a GSK partnership. Biopharma customers now represent 49% of revenue. Gross profit rose to $20.6M, but operating loss widened to $15.1M. The company raised its 2026 revenue guidance to $121M-$123M. ALMR plans to submit its ARGO HT/DX clinical instrument for FDA approval by late 2027.

Med

Alamar Q3 2026 presentation: consumables surge, guidance raised

Alamar Biosciences reported Q3 2026 revenue of $33.5M, up 68% YoY, driven by a 79% surge in consumables sales. The company raised its full-year outlook, citing strong biopharma customer demand and research partnerships. Gross margin improved to 61.5%, but net loss widened to $13.3M due to increased operating expenses. The stock closed at $30.22, up 4.42%, before slipping in after-hours trading.

$ALMRMed

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance FREMONT, Calif. Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection o